TrianglePUBLICATIONS · 29719113
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Pediatr Blood Cancer
- Publication date
- 2018 Aug
- First author
- Schafer ES
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Schafer ES
- type
- Author
- name
- Rau RE
- type
- Author
- name
- Berg S
- type
- Author
- name
- Liu X
- type
- Author
- name
- Minard CG
- type
- Author
- name
- D'Adamo D
- type
- Author
- name
- Scott R
- type
- Author
- name
- Reyderman L
- type
- Author
- name
- Martinez G
- type
- Author
- name
- Devarajan S
- type
- Author
- name
- Reid JM
- type
- Author
- name
- Fox E
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Schafer ES
- type
- Author
- name
- Rau RE
- type
- Author
- name
- Berg S
- type
- Author
- name
- Liu X
- type
- Author
- name
- Minard CG
- type
- Author
- name
- D'Adamo D
- type
- Author
- name
- Scott R
- type
- Author
- name
- Reyderman L
- type
- Author
- name
- Martinez G
- type
- Author
- name
- Devarajan S
- type
- Author
- name
- Reid JM
- type
- Author
- name
- Fox E
- type
- Author
- bibliography ids
- nci-bib-703842fcc21719c9a0222a77
- book metadata
- content sha256
- c11a5f29157ba7e37205d5d7e675856a2629a6cc6acefb69aa0f8a7b5fcf538c
- document type
- citation
- dois
- 10.1002/pbc.27066
- electronic publication date
- display
- 2018 May 2
- precision
- day
- year
- 2018
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:29719113
- immutable id
- pubmed:29719113@c11a5f29157ba7e37205d5d7e675856a2629a6cc6acefb69aa0f8a7b5fcf538c
- journal
- abbreviation
- Pediatr Blood Cancer
- issn electronic
- 1545-5017
- issn print
- 1545-5009
- issue
- 8
- name
- Pediatric blood & cancer
- nlm unique id
- 101186624
- pages
- e27066
- volume
- 65
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 29719113
- provenance
- batch id
- c4c0356d060413f719c2
- provider
- NCBI PubMed ESummary
- record sha256
- c39d415b23239adcde23e1863d3deb70bf6a6f06ff59f5a39fbdb7b8a1949834
- response sha256
- adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
- retrieved at
- 2026-09-09T23:47:33.674758+00:00
- publication date
- display
- 2018 Aug
- precision
- month
- year
- 2018
- publication types
- Clinical Trial, Phase I
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Preserved source evidence · Not medical advice